Introduction. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) is a rare genetic ventricular tachycardia which can result in sudden cardiac death and/or syncope in young individuals ...

Solid Biosciences said federal regulators have granted its fast-track designation for the company's investigational gene therapy for the treatment of a heart rhythm condition.

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a heart condition marked by abnormal rhythms; specifically, an abnormally fast heartbeat (ventricular tachycardia), which can be ...

Solid Biosciences Inc. (NASDAQ: SLDB) shares made moderate gains at first. The Charlestown, Mass.-based concern, a clinical stage life sciences company developing precision genetic medicines for ...

Trial to investigate the safety and efficacy of ARM210 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Lead molecule ARM210 repairs ‘leaky’ Ryanodine Receptor ...

Charlestown, Massachusetts Thursday, July 10, 2025, 15:30 Hrs [IST] ...

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a heart condition marked by abnormal rhythms; specifically, an abnormally fast heartbeat (ventricular tachycardia), which can be ...

She didn’t know that she was suffering the symptoms of an inherited gene mutation, Catecholaminergic polymorphic ventricular tachycardia (CPVT), which had gone undetected for 25 years.

ARMGO Pharma, Inc. (ARMGO), a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs known as Rycals, announced the enrollment of the first patient in a phase 2 proof ...

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Solid Biosciences Inc.

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a heart condition marked by abnormal rhythms; specifically, an abnormally fast heartbeat (ventricular tachycardia), which can be ...